Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study

Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study

Show other versions (1)
Bibliographic Details
Main Author: James R. Crandell
Format: Article
Language:English
Published: SAGE Publishing 2016-07-01
Series:Clinical Medicine Insights: Cardiology
Online Access:http://www.la-press.com/switching-from-epa--dha-omega-3-acid-ethyl-esters-to-high-purity-epa-i-article-a5790
id doaj-38a89e6397e54eedbc481e51228d51b7
record_format Article
spelling doaj-38a89e6397e54eedbc481e51228d51b72020-11-25T03:24:07ZengSAGE PublishingClinical Medicine Insights: Cardiology1179-54682016-07-012016101231285790Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case StudyJames R. Crandellhttp://www.la-press.com/switching-from-epa--dha-omega-3-acid-ethyl-esters-to-high-purity-epa-i-article-a5790
collection DOAJ
language English
format Article
sources DOAJ
author James R. Crandell
spellingShingle James R. Crandell
Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study
Clinical Medicine Insights: Cardiology
author_facet James R. Crandell
author_sort James R. Crandell
title Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study
title_short Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study
title_full Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study
title_fullStr Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study
title_full_unstemmed Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study
title_sort switching from epa + dha (omega-3-acid ethyl esters) to high-purity epa (icosapent ethyl) in a statin-treated patient with persistent dyslipidemia and high cardiovascular risk: a case study
publisher SAGE Publishing
series Clinical Medicine Insights: Cardiology
issn 1179-5468
publishDate 2016-07-01
url http://www.la-press.com/switching-from-epa--dha-omega-3-acid-ethyl-esters-to-high-purity-epa-i-article-a5790
work_keys_str_mv AT jamesrcrandell switchingfromepadhaomega3acidethylesterstohighpurityepaicosapentethylinastatintreatedpatientwithpersistentdyslipidemiaandhighcardiovascularriskacasestudy
_version_ 1724603283557842944

Similar Items